Preferred Label : Batimastat;
NCIt synonyms : Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-,
(2R-(1(S*),2R*,3S*))-; (2R,3S)-N{4}-Hydroxy-N{1}-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide; [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide; [4-(N-Hydroxyamino)-2R-isobutyl-3S-(thiophen-2-ylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide;
NCIt definition : A synthetic hydroxamate with potential antineoplastic activity. Batimastat binds covalently
to the zinc ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting
the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis,
tumor growth and invasion, and metastasis. (NCI04);
Alternative definition : NCI-GLOSS: An anticancer drug that belongs to the family of drugs called angiogenesis
inhibitors. Batimastat is a matrix metalloproteinase inhibitor.;
UNII : BK349F52C9;
InChIKey : XFILPEOLDIKJHX-QYZOEREBSA-N;
CAS number : 130370-60-4;
Molecule name : BB-94;
Chemical formula : C23H31N3O4S2;
Codes from synonyms : CDR0000046135; 09358;
Origin ID : C1529;
UMLS CUI : C0215791;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
